- Home
- CLLS vs INBX Comparison
CLLS vs INBX Comparison
Compare CLLS & INBX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | CLLS | INBX |
|---|---|---|
| Founded | 1999 | 2010 |
| Country | France | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 476.5M | 430.2M |
| IPO Year | 2007 | 2020 |
Fundamental Metrics
Financial Performance| Metric | CLLS | INBX |
|---|---|---|
| Price | $4.38 | $78.27 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 2 | 2 |
| Target Price | ★ $8.50 | N/A |
| AVG Volume (30 Days) | 114.5K | ★ 257.5K |
| Earning Date | 11-07-2025 | 11-14-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $82,551,000.00 | $1,400,000.00 |
| Revenue This Year | $32.58 | $563.00 |
| Revenue Next Year | $20.68 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 129.04 | N/A |
| 52 Week Low | $1.10 | $10.81 |
| 52 Week High | $5.48 | $94.57 |
Technical Indicators
Market Signals| Indicator | CLLS | INBX |
|---|---|---|
| Relative Strength Index (RSI) | 51.37 | 45.80 |
| Support Level | $4.37 | $74.46 |
| Resistance Level | $4.97 | $82.34 |
| Average True Range (ATR) | 0.25 | 5.71 |
| MACD | -0.04 | -1.19 |
| Stochastic Oscillator | 62.78 | 11.12 |
Price Performance
Historical ComparisonAbout CLLS Cellectis S.A.
Cellectis SA is a clinical stage biotechnological company, employing the core proprietary technologies to develop products based on gene-editing, with a portfolio of allogeneic Chimeric Antigen Receptor T-cells, or UCART, product candidates in the field of immuno-oncology and gene-edited hematopoietic stem and progenitor cells, or HSPC product candidates in other therapeutic indications.
About INBX Inhibrx Inc.
Inhibrx Biosciences Inc is a clinical-stage biopharmaceutical company with a pipeline of novel biologic therapeutic candidates, developed using its proprietary modular protein engineering platforms. Its clinical pipeline of therapeutic candidates includes INBRX-109 and INBRX-106, both of which utilize their multivalent formats where the precise valency can be optimized in a target-centric way to mediate what experts consider to be the predominant agonist function.